877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
New Search    Reset Filters

Similar to AC1LIG26
, Serotonin reuptake inhibitors

Categories

Aromatic compounds (1)
Cyclic compounds (1)
Drugs acting on the nervous system (1)
Fluoroarenes (1)
Monoamine reuptake inhibitors (1)
Nervous system drug (1)
Psychoactive drugs (1)

AC1LIG26  
3-(4-fluorophenyl)-3-phenylpropanoic acid  ·  362-86-7
Delucemine (186495-49-8)  
Delucemine (NPS-1506) is a drug which acts as an NMDA antagonist and a serotonin reuptake inhibitor, and has neuroprotective effects. It was originally investigated for the treatment of stroke and in 2004 was studied as a potential antidepressant.

Related Results:
Nisoxetine (53179-07-0, 57754-86-6, 57226-61-6)  
3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine  ·  LY 135252  ·  N-methyl-gamma-(2-methylphenoxy)phenylpropanolamine
Nisoxetine, originally synthesized in the Lilly research laboratories during the early 1970s, is a potent and selective inhibitor for the reuptake of norepinephrine (noradrenaline) into synapses. It currently has no clinical applications in humans, although it was originally researched as an antidepressant. Nisoxetine is now widely used in scientific research as a standard selective norepinephrine reuptake inhibitor.
Milnacipran (92623-85-3, 96847-55-1)  
Milnacipran (trade names Ixel, Savella, Dalcipran, Toledomin) is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia. It is not approved for the clinical treatment of major depressive disorder in the USA, but it is in other countries.
Reboxetine (98769-81-4, 98819-76-2, 71620-89-8)  
Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective in comparison. However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.
Zimelidine dihydrochloride (60525-15-7)  
Zimelidine  ·  Zimeldine  ·  H-102-09
Brofaromine (63638-91-5)  
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.
citalopram (59729-33-8)  
Escitalopram  ·  Lexapro  ·  Cytalopram
Citalopram (brand names: Celexa, Cipramil and others) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration approval to treat major depression, which it received in 1998, and is prescribed off-label for other conditions.
citalopram hydrobromide (59729-32-7)  
Citalopram (brand names: Celexa, Cipramil and others) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration approval to treat major depression, which it received in 1998, and is prescribed off-label for other conditions.
Nomifensine (24526-64-5, 89664-20-0)  
Merital  ·  Nomifensine Maleate  ·  Nomifensine Maleate (1:1)
Nomifensine (Merital, Alival) is a norepinephrine-dopamine reuptake inhibitor, i.e. a drug that increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters. This is a mechanism of action shared by some recreational drugs like cocaine and the medication tametraline (see DRI).
fluoxetine (54910-89-3)  
Prozac  ·  Fluoxetine Hydrochloride  ·  Sarafem
Fluoxetine, also known by trade names Prozac and Sarafem among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It may decrease the risk of suicide in those over the age of 65.
Nomifensine maleate (32795-47-4)  
Nomifensine  ·  Merital  ·  Nomifensine Maleate (1:1)
(Z) Fluvoxamine (54739-18-3)  
Fluvoxamine  ·  Luvox  ·  Fluvoxamine Maleate
mianserin (78684-63-6, 24219-97-4)  
Mianserin Hydrochloride  ·  Org GB 94  ·  Tolvon
Mianserin, sold under the brand name Tolvon among others, is an atypical antidepressant which is used in the treatment of depression in Europe and elsewhere in the world. It is a tetracyclic antidepressant (TeCA). Mianserin is closely related to mirtazapine, both chemically and in terms of its actions and effects, although there are significant differences between the two drugs.
TETRABENAZINE (58-46-8)  
Nitoman  ·  Orphan Brand of Tetrabenazine  ·  Tetrabenazine Orphan Brand
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand, some parts of Europe and in the United States as an orphan drug. On August 15, 2008, the U.S.
Alaproclate (60719-82-6)  
alaproclate hydrochloride, (D)-isomer  ·  A 23189  ·  alaproclate hydrochloride
Alaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies.
ritanserin (87051-43-2)  
Ritanserin (INN, USAN, BAN) is a serotonin receptor antagonist which was never marketed for clinical use but has been used in scientific research.
pargyline (555-57-7)  
Pargyline Hydrochloride
Pargyline (brand name Eutonyl) is an irreversible selective monoamine oxidase (MAO)-B inhibitor drug (IC50 for MAO-A is 0.01152 µmol/L and for MAO-B is 0.00820 µmol/L) It was brought to market in the US and the UK by Abbott in 1963 as an antihypertensive drug branded "Eutonyl". It was one of several MAO inhibitors introduced in the 1960s including nialamide, isocarboxazid, phenelzine, and tranylcypromine. By 2007 the drug was discontinued and as of 2014 there were no generic versions available in the US.
2-Phenylcyclopropanamine (155-09-9)  
Tranylcypromine (contracted from trans-2-phenylcyclopropylamine; original trade name Parnate) is a monoamine oxidase inhibitor (MAOI); more specifically, tranylcypromaine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively. Tranylcypromine is a propylamine formed from the cyclization of amphetamine's side chain; therefore, it is classified as a substituted amphetamine.
Levofenfluramine (37577-24-5)  
Levofenfluramine (INN), or (−)-3-trifluoromethyl-N-ethylamphetamine, also known as (−)-fenfluramine or (R)-fenfluramine, is a drug of the amphetamine family that, itself (i.e., in enantiopure form), was never marketed. It is the levorotatory enantiomer of fenfluramine, the racemic form of the compound, whereas the dextrorotatory enantiomer is dexfenfluramine. Both fenfluramine and dexfenfluramine are anorectic agents that have been used clinically in the treatment of obesity (and hence, levofenfluramine has been as well since it is a component of fenfluramine).
Next Page >